Table 1.
Characteristics of included randomized clinical trials in this analysis.
| References | Study name | Samples (experiment/control) | Intervention (experiment group) | Intervention (control group) | Primary outcome |
|---|---|---|---|---|---|
| Chi et al. (5) | TITAN | 525/527 | ADT + Apalutamide (240 mg/d) | ADT | OS, rPFS |
| James et al. (2) | STAMPEDE-G arm | 960/957 | ADT + Abiraterone (1,000 mg/d) + Prednisolone (5 mg/d) | ADT | OS, FFS |
| Fizazi et al. (15) | LATITUDE | 597/602 | ADT + Abiraterone (1,000 mg/d) + Prednisolone (5 mg/d) | ADT | OS, rPFS |
| Gravis et al. (16) | GETUG-AFU-15 | 192/193 | ADT + Docetaxel (75 mg/m2 for 21 d, up to 9 cycles) | ADT | OS |
| Sweeney et al. (12) | CHAARTED | 397/393 | ADT + Docetaxel (75 mg/m2 for 21 d, up to 9 cycles) | ADT | OS |
| Clarke et al. (17) | STAMPEDE-C arm | 592/1,184 | ADT + Docetaxel (75 mg/m2 for 21 d, up to 6-cycle) | ADT | OS |
| Davis et al. (4) | ENZAMET | 563/562 | ADT + Enzalutamide (160 mg/d) | ADT | OS, PFS |
| Armstrong et al. (6) | ARCHES | 574/576 | ADT + Enzalutamide (160 mg/d) | ADT | rPFS |
| Boevé et al. (8) | HORRAD | 216/216 | ADT + external beam radiation therapy | ADT | OS |
| Parker et al. (9) | STAMPEDE-H arm | 1,032/1,029 | ADT + external beam radiation therapy | ADT | OS, FFS |
OS, Overall survival; rPFS, radiographic progression-free survival; PFS, progression-free survival; FFS, failure-free survival; bPFS, biochemical progression-free survival; ADT, androgen deprivation therapy.